PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 8835930-0 1996 Effects of ebelactone B, a lipase inhibitor, on intestinal fat absorption in the rat. ebelactone B 11-23 lipase G, endothelial type Rattus norvegicus 27-33 8835628-0 1995 Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon. ebelactone B 131-143 kininogen 1 Homo sapiens 15-25 8835628-3 1995 The combination of phosphoramidon and ebelactone B completely (by 95%) inhibited bradykinin degradation in human urine. ebelactone B 38-50 kininogen 1 Homo sapiens 81-91 21062953-5 2011 The phospholipase activity detected by the PLA1 substrate could be inhibited with the small molecule esterase inhibitor ebelactone B. ebelactone B 120-132 lipase H Homo sapiens 43-47 12576084-4 2003 The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin. ebelactone B 40-52 cathepsin A Homo sapiens 4-13 14737963-0 2003 Effects of ebelactone B on cathepsin A activity in intact platelets and on platelet activation. ebelactone B 11-23 cathepsin A Homo sapiens 27-38 14737963-1 2003 PURPOSE: Previous in vitro studies have demonstrated that a potent antihypertensive agent ebelactone B inhibits cathepsin A/deamidase activity. ebelactone B 90-102 cathepsin A Homo sapiens 112-133 14737963-6 2003 RESULTS: Pre-treatment of platelets for up to 60 minutes with 10 mumol/l ebelactone B, that effectively inhibits cathepsin A activity in platelet lysate, did not affect this activity in intact platelets. ebelactone B 73-85 cathepsin A Homo sapiens 113-124 14737963-7 2003 Exposure of PRP to 10 mumol/l ebelactone B alone, or before platelet activation with ADP or TRAP caused only a small but non-significant increase in P-selectin and GpIIb/IIIa expression on the platelet surface, as demonstrated by flow cytometry analysis. ebelactone B 30-42 prion protein Homo sapiens 12-15 14737963-7 2003 Exposure of PRP to 10 mumol/l ebelactone B alone, or before platelet activation with ADP or TRAP caused only a small but non-significant increase in P-selectin and GpIIb/IIIa expression on the platelet surface, as demonstrated by flow cytometry analysis. ebelactone B 30-42 selectin P Homo sapiens 149-159 14737963-7 2003 Exposure of PRP to 10 mumol/l ebelactone B alone, or before platelet activation with ADP or TRAP caused only a small but non-significant increase in P-selectin and GpIIb/IIIa expression on the platelet surface, as demonstrated by flow cytometry analysis. ebelactone B 30-42 integrin subunit alpha 2b Homo sapiens 164-169 8089934-1 1994 Ebelactone B (EB) (10(-7)-10(-5) M) inhibited dose-dependently carboxypeptidase (CP) Y-like exopeptidase, one of the major kininases separated from rat urine, whereas it inhibited neither CPA, CPB or neutral endopeptidase (NEP). ebelactone B 0-12 carboxypeptidase B1 Rattus norvegicus 193-196 8089934-1 1994 Ebelactone B (EB) (10(-7)-10(-5) M) inhibited dose-dependently carboxypeptidase (CP) Y-like exopeptidase, one of the major kininases separated from rat urine, whereas it inhibited neither CPA, CPB or neutral endopeptidase (NEP). ebelactone B 0-12 membrane metallo-endopeptidase Rattus norvegicus 200-221 8089934-1 1994 Ebelactone B (EB) (10(-7)-10(-5) M) inhibited dose-dependently carboxypeptidase (CP) Y-like exopeptidase, one of the major kininases separated from rat urine, whereas it inhibited neither CPA, CPB or neutral endopeptidase (NEP). ebelactone B 0-12 membrane metallo-endopeptidase Rattus norvegicus 223-226 8089934-1 1994 Ebelactone B (EB) (10(-7)-10(-5) M) inhibited dose-dependently carboxypeptidase (CP) Y-like exopeptidase, one of the major kininases separated from rat urine, whereas it inhibited neither CPA, CPB or neutral endopeptidase (NEP). ebelactone B 14-16 carboxypeptidase B1 Rattus norvegicus 193-196 8089934-1 1994 Ebelactone B (EB) (10(-7)-10(-5) M) inhibited dose-dependently carboxypeptidase (CP) Y-like exopeptidase, one of the major kininases separated from rat urine, whereas it inhibited neither CPA, CPB or neutral endopeptidase (NEP). ebelactone B 14-16 membrane metallo-endopeptidase Rattus norvegicus 200-221 8089934-1 1994 Ebelactone B (EB) (10(-7)-10(-5) M) inhibited dose-dependently carboxypeptidase (CP) Y-like exopeptidase, one of the major kininases separated from rat urine, whereas it inhibited neither CPA, CPB or neutral endopeptidase (NEP). ebelactone B 14-16 membrane metallo-endopeptidase Rattus norvegicus 223-226 22861813-4 2012 Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension. ebelactone B 58-70 cathepsin A Homo sapiens 30-34 22861813-4 2012 Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension. ebelactone B 58-70 kininogen 1 Homo sapiens 87-97 15842622-7 2005 Ebelactone B, a known lipase inhibitor, repressed the lipolytic activity of the enzyme. ebelactone B 0-12 probable feruloyl esterase A Triticum aestivum 22-28 11180979-6 2001 Both the acylpeptide hydrolase activity and the protease activity of the 55 kDa enzyme were completely inhibited by diisopropylfluorophosphate, p -chloromercuribenzoate and ebelactone, and moderately inhibited by N -tosyl phenylalanine chloromethyl ketone. ebelactone B 173-183 acylaminoacyl-peptide hydrolase Bos taurus 9-30